A new evidence report on vitamin D and bone health reviews the current scientific evidence and identifies its strengths and weaknesses. This report will be a valuable resource for an upcoming National Institutes of Health conference September 5-6 that will examine a range of scientific perspectives related to vitamin D and bone health across the lifecycle.
Children who carry variations in specific genes that metabolize vehicle emissions are more susceptible to developing asthma, particularly if they live near major roadways, a study led by researchers at the University of Southern California (USC) suggests.
A study led by a team of researchers at Oregon Health & Science University has demonstrated for the first time that molecular imaging with contrast-enhanced ultrasound and targeted microbubbles is effective in detecting at a very early stage inflammatory processes that lead to atherosclerosis.
Ineffective or even dangerous fad treatments for autism, always a problem, seem to be growing more pervasive, according to researchers who studied the problem.
A new University of Georgia study finds that pectin, a type of fiber found in fruits and vegetables and used in making jams and other foods, kills prostate cancer cells.
A study in the August 21st issue of Current Biology, a publication of Cell Press, reports some of the first conclusive evidence in support of the long-held notion that men and women differ when it comes to their favorite colors.
Scientists reported new evidence that infection with a common virus may be a contributing factor to the obesity epidemic sweeping through the United States and other countries.
Understanding the molecular structures of compounds that give certain fruits and vegetables their rich colors may help researchers find even more powerful cancer fighters, a new study suggests.
Findings from a study released revealed that a limited amount of clinical research exists to prove the effectiveness of many over-the-counter (OTC) anti-aging products.
Dendreon Corporation (Nasdaq: DNDN) announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology.